IFN-β can sensitive GBM cells to TMZ by suppressing MGMT activity [92], although the SOC + IFN-β did not lead to a significant survival benefit in the phase II INTEGRA trial [93]. This evidence concerns the gene IFNB1 and glioblastoma.